oxaliplatin, irinotecan
Phase 2Small molecule
oxaliplatin, irinotecan is one of 29 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
SHR-1210
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
oxaliplatin, irinotecan
DDong-A University Hospital
Phase 2
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Marginal Zone B-Cell Lymphoma1 trial
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
Completed·—·Phase 2·NCT01068392·42 enrolled
Gastric Cancer1 trial
FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)
Completed·—·Phase 2·NCT01138904·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oxaliplatin, irinotecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDong-A University Hospital